Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scFv-Fc-scFv) is designed to be expressed as one chain, then assembled to a homodimer of bivalent scFv fragments and the Fc region of IgG. The anti-CD64 scFv is fused to the N-terminus of Fc via a hinge region while another anti-EGFR scFv is linked to the C-terminus of Fc. This scFv-Fc-scFv format has 2+2 antigen-binding valency by employing different scFv fragments. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.